RxDoctor Payments Data

Alexander Barsam, MD

Ophthalmology · Saint Louis, MONPI 1578914974

Payments from drug & device makers

$3,473in general payments, 2019–2025

Across 68 payments — averaging $51.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$2K
  • Johnson & Johnson Surgical Vision, Inc.$545
  • Sight Sciences, Inc.$222
  • Bausch & Lomb Americas Inc.$148
  • Biotissue Holdings Inc.$122
  • AbbVie$93
  • plus $184 from 5 others

What the payments were for

  • Food & beverage$3,473100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,473 in reported general payments places this provider in the 60th percentile of 286 ophthalmology providers in Missouri.

See all ophthalmology providers in Missouri

Medicare billing

Part B allowed, 2024
$168,130
Medicare patients
517
Services billed
1,406

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine36$31,212
Fluorometholone77$4,774
Prednisolone Acetate112$3,988
Latanoprost312$3,268
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol18$3,079
LumiganBimatoprost11$3,072
Tobramycin-DexamethasoneTobramycin/Dexamethasone23$1,162
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat81$1,129
Timolol Maleate72$735
ErythromycinErythromycin Base48$452
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha38$441
Ofloxacin39$416
Dorzolamide Hcl23$363
Ketorolac Tromethamine22$353
Brimonidine Tartrate47$321

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$93$34,28447 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 286 ophthalmology providers in Missouri.

Other ophthalmology in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →